Zostautiene Ieva, Jorde Rolf, Schirmer Henrik, Mathiesen Ellisiv Bøgeberg, Njølstad Inger, Løchen Maja-Lisa, Wilsgaard Tom, Joakimsen Ragnar Martin, Kamycheva Elena
Tromsø Endocrine Research Group, Department of Clinical Medicine, UiT The Arctic University of Norway, Tromsø, Norway.
Division of Internal Medicine, University Hospital of North Norway, Tromsø, Norway.
PLoS One. 2015 Dec 23;10(12):e0145359. doi: 10.1371/journal.pone.0145359. eCollection 2015.
Though the associations between low serum 25-hydroxyvitamin D (25(OH)D) levels and health outcomes such as type 2 diabetes (T2D), myocardial infarction (MI), cancer, and mortality are well-studied, the effect of supplementation with vitamin D is uncertain. This may be related to genetic differences. Thus, rs7968585, a single nucleotide polymorphism (SNP) of the vitamin D receptor (VDR), has recently been reported as a predictor of composite health outcome. We therefore aimed to evaluate whether rs7968585 predicts separate clinical outcomes such as T2D, MI, cancer, and mortality in a community-based Norwegian population.
Measurements and DNA were obtained from the participants in the Tromsø Study in 1994-1995, registered with the outcomes of interest and a randomly selected control group. The impact of the rs7968585 genotypes was evaluated with Cox proportional hazards. A total of 8,461 subjects were included among whom 1,054 subjects were registered with T2D, 2,287 with MI, 3,166 with cancer, and 4,336 with death. Mean follow-up time from birth was 60.8 years for T2D and MI, 61.2 years for cancer, while mean follow-up time from examination date was 16.5 years for survival. Mean serum 25(OH)D levels did not differ across the rs7968585 genotypes. With the major homozygote genotype as reference, the minor homozygote subjects had hazard ratios of 1.25 (95% CI 1.05-1.49) for T2D and 1.14 (1.02-1.28) for MI (P = 0.011 and 0.023, respectively, without the Bonferroni correction). No significant interaction between serum 25(OH)D status and the rs7968585 genotype was found for any of the endpoints.
The VDR-related SNP rs7968585 minor allele is a significant and positive predictor for T2D and possibly for MI. Since the functional mechanism of this SNP is not yet understood, and the association with T2D is reported for the first time, confirmatory studies are needed.
尽管血清25-羟基维生素D(25(OH)D)水平低下与2型糖尿病(T2D)、心肌梗死(MI)、癌症及死亡率等健康结局之间的关联已得到充分研究,但维生素D补充剂的效果仍不确定。这可能与基因差异有关。因此,维生素D受体(VDR)的单核苷酸多态性(SNP)rs7968585最近被报道为综合健康结局的预测指标。我们旨在评估rs7968585是否能预测挪威社区人群中T2D、MI、癌症及死亡率等单独的临床结局。
1994 - 1995年从特罗姆瑟研究的参与者中获取测量数据和DNA,记录感兴趣的结局并随机选择一个对照组。采用Cox比例风险模型评估rs7968585基因型的影响。共纳入8461名受试者,其中1054名患有T2D,2287名患有MI,3166名患有癌症,4336名死亡。T2D和MI从出生起的平均随访时间为60.8年,癌症为61.2年,生存情况从检查日期起的平均随访时间为16.5年。rs7968585各基因型的平均血清25(OH)D水平无差异。以主要纯合子基因型为参照,次要纯合子受试者患T2D的风险比为1.25(95%可信区间1.05 - 1.49),患MI的风险比为1.14(1.02 - 1.28)(未进行Bonferroni校正时,P值分别为0.011和0.023)。对于任何终点,均未发现血清25(OH)D状态与rs7968585基因型之间存在显著相互作用。
VDR相关的SNP rs7968585次要等位基因是T2D以及可能是MI的显著正向预测指标。由于该SNP的功能机制尚不清楚,且与T2D的关联首次被报道,因此需要进行验证性研究。